• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune Checkpoint Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer: A Report of Two Cases.

作者信息

Jain Aditya, Fujioka Naomi, Patel Manish

机构信息

Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.

Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.

出版信息

J Thorac Oncol. 2019 Aug;14(8):e165-e167. doi: 10.1016/j.jtho.2019.03.008.

DOI:10.1016/j.jtho.2019.03.008
PMID:31345337
Abstract
摘要

相似文献

1
Immune Checkpoint Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer: A Report of Two Cases.ROS1重排的非小细胞肺癌中的免疫检查点抑制剂：两例报告
J Thorac Oncol. 2019 Aug;14(8):e165-e167. doi: 10.1016/j.jtho.2019.03.008.
2
High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.ROS1重排的非小细胞肺癌循环肿瘤细胞中高水平的染色体不稳定性
Ann Oncol. 2015 Jul;26(7):1408-15. doi: 10.1093/annonc/mdv165. Epub 2015 Apr 6.
3
Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.非小细胞肺癌ROS1融合重排患者酪氨酸激酶抑制剂治疗的检测方法比较及随访研究
BMC Cancer. 2016 Aug 4;16:599. doi: 10.1186/s12885-016-2582-9.
4
Crizotinib in ROS1-rearranged non-small-cell lung cancer.克唑替尼用于ROS1重排的非小细胞肺癌
N Engl J Med. 2015 Feb 12;372(7):683-4. doi: 10.1056/NEJMc1415359.
5
Crizotinib in ROS1-rearranged non-small-cell lung cancer.克唑替尼用于ROS1重排的非小细胞肺癌
N Engl J Med. 2015 Feb 12;372(7):683. doi: 10.1056/NEJMc1415359.
6
Validating ROS1 rearrangements as a therapeutic target in non-small-cell lung cancer.验证ROS1重排在非小细胞肺癌中作为治疗靶点的作用。
J Clin Oncol. 2015 Mar 20;33(9):972-4. doi: 10.1200/JCO.2014.59.8334. Epub 2015 Feb 9.
7
Two Cases of Pulmonary Tumor Thrombotic Microangiopathy Associated with ROS1-Rearranged Non-Small-Cell Lung Cancer.两例与ROS1重排非小细胞肺癌相关的肺肿瘤血栓性微血管病
Clin Lung Cancer. 2021 Mar;22(2):e153-e156. doi: 10.1016/j.cllc.2020.09.020. Epub 2020 Oct 15.
8
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.培美曲塞为主的全身治疗在RET重排肺癌中的临床疗效。
Ann Oncol. 2016 Jul;27(7):1286-91. doi: 10.1093/annonc/mdw163. Epub 2016 Apr 7.
9
ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses.ROS1重排的非小细胞肺癌、因子V莱顿突变与复发性静脉血栓形成
Clin Lung Cancer. 2018 Sep;19(5):457-459. doi: 10.1016/j.cllc.2018.05.015. Epub 2018 Jun 5.
10
[Crizotinib for ROS1-rearranged non-small cell lung cancer patients].克唑替尼用于ROS1重排的非小细胞肺癌患者
Bull Cancer. 2017 Apr;104(4):303-310. doi: 10.1016/j.bulcan.2017.01.008. Epub 2017 Feb 22.

引用本文的文献

1
Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review.免疫疗法对癌基因成瘾的非小细胞肺癌患者有益吗？一项叙述性综述。
Cancers (Basel). 2024 Jan 26;16(3):527. doi: 10.3390/cancers16030527.
2
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.非小细胞肺癌（NSCLC）癌基因成瘾亚群免疫治疗的十字路口
Nat Rev Clin Oncol. 2023 Mar;20(3):143-159. doi: 10.1038/s41571-022-00718-x. Epub 2023 Jan 13.
3
Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy.
评估 PD-L1 阳性转移性非小细胞肺癌的分子谱：来自意大利坎帕尼亚的数据。
Int J Mol Sci. 2022 Aug 1;23(15):8541. doi: 10.3390/ijms23158541.
4
Rare Fusion Gene-Positive Lung Adenocarcinoma Showing Response to Entrectinib Treatment: A Case Study.罕见的融合基因阳性肺腺癌对恩曲替尼治疗有反应：病例报告
Case Rep Oncol. 2022 Mar 31;15(1):376-381. doi: 10.1159/000524071. eCollection 2022 Jan-Apr.
5
[Research Progress of Immunotherapy for Non-small Cell Lung Cancer 
with Drive Gene Mutation].[驱动基因突变的非小细胞肺癌免疫治疗研究进展]
Zhongguo Fei Ai Za Zhi. 2022 Mar 20;25(3):201-206. doi: 10.3779/j.issn.1009-3419.2022.102.06.
6
Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer.非小细胞肺癌中的免疫检查点抑制剂与驱动癌基因
Transl Cancer Res. 2019 Dec;8(Suppl 6):S628-S632. doi: 10.21037/tcr.2019.10.08.
7
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic -Rearranged Lung Cancers.免疫检查点抑制剂单药治疗或联合化疗用于转移性重排肺癌的疗效
JTO Clin Res Rep. 2021 May 18;2(7):100187. doi: 10.1016/j.jtocrr.2021.100187. eCollection 2021 Jul.
8
Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with -rearranged lung adenocarcinoma.阿来替尼治疗后耐药的伴有-重排肺腺癌患者的免疫化疗短期应答和免疫特征。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001967.